
Opinion|Videos|December 9, 2025
Current Treatment Standards in Metastatic Uveal Melanoma
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), highlight current treatment approaches in metastatic uveal melanoma.
Advertisement
Episodes in this series

Prof.Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), review current therapeutic standards in metastatic uveal melanoma, emphasizing the unique biology of this rare malignancy and its predominantly hepatic pattern of spread. They highlight available systemic options, including immunotherapies and targeted approaches, and note the limitations in response rates compared with cutaneous melanoma. Forschner and Khan also address ongoing challenges in optimizing patient outcomes and the need for more effective, liver-directed treatment strategies.
Advertisement
Related to this article

Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5



